NVS Novartis AG

   By Ed Frankl 
 

Novartis said Friday that its prostate-cancer treatment 177Lu-PSMA-617 produced positive quality-of-life results in a Phase 3 study.

The treatment is an investigational targeted radioligand therapy to treat metastatic castration-resistant prostate cancer, Novartis said.

The Swiss pharmaceutical company said the Phase 3 Vision data showed delayed worsening of symptoms with 177Lu-PSMA-617 plus standard of care, compared to standard of care alone.

"These new data emphasize the potential impact on quality of life that investigational 177Lu-PSMA-617 may provide as a potential new treatment option," said Jeff Legos, global head of oncology development at Novartis.

The company in June received FDA breakthrough therapy designation for 177Lu-PSMA-617 in patients with prostate cancer.

Write to Ed Frankl at edward.frankl@dowjones.com

(END) Dow Jones Newswires

September 17, 2021 01:38 ET (05:38 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.